全文获取类型
收费全文 | 3614篇 |
免费 | 275篇 |
国内免费 | 12篇 |
学科分类
医药卫生 | 3901篇 |
出版年
2023年 | 17篇 |
2022年 | 28篇 |
2021年 | 52篇 |
2020年 | 43篇 |
2019年 | 88篇 |
2018年 | 95篇 |
2017年 | 74篇 |
2016年 | 77篇 |
2015年 | 68篇 |
2014年 | 104篇 |
2013年 | 125篇 |
2012年 | 124篇 |
2011年 | 142篇 |
2010年 | 100篇 |
2009年 | 112篇 |
2008年 | 191篇 |
2007年 | 145篇 |
2006年 | 155篇 |
2005年 | 146篇 |
2004年 | 140篇 |
2003年 | 135篇 |
2002年 | 145篇 |
2001年 | 137篇 |
2000年 | 125篇 |
1999年 | 132篇 |
1998年 | 52篇 |
1997年 | 43篇 |
1996年 | 40篇 |
1995年 | 37篇 |
1994年 | 37篇 |
1993年 | 24篇 |
1992年 | 116篇 |
1991年 | 101篇 |
1990年 | 91篇 |
1989年 | 87篇 |
1988年 | 71篇 |
1987年 | 59篇 |
1986年 | 58篇 |
1985年 | 51篇 |
1984年 | 49篇 |
1983年 | 15篇 |
1982年 | 24篇 |
1980年 | 20篇 |
1979年 | 24篇 |
1978年 | 14篇 |
1977年 | 15篇 |
1972年 | 15篇 |
1971年 | 15篇 |
1970年 | 12篇 |
1968年 | 17篇 |
排序方式: 共有3901条查询结果,搜索用时 15 毫秒
1.
F Elferink W J van der Vijgh W W ten Bokkel Huinink J B Vermorken I Klein B Winograd M K Knobf G Simonetti H E Gall J G McVie 《British journal of cancer》1987,56(4):479-483
Pharmacokinetics of the cis-platin analog ethylenediaminemalonatoplatinum(II) (JM-410) was studied in 28 cycles of 19 patients during the phase I study of this drug. The drug was administered intravenously by short-term (10-60 min) infusion. Doses ranged from 20 to 1,200mg m-2. JM-40 was determined in plasma ultrafiltrate and urine by HPLC. Platinum (Pt) concentrations were determined in plasma, plasma ultrafiltrate, urine and red blood cells by atomic absorption spectrometry up to 5 days after administration of the drug. Ultrafilterable Pt could be determined up to 45 days after the infusion in one patient sampled over such a long period. Pharmacokinetics of JM-40 showed a linear behaviour. The final half-life of total Pt in plasma was 4.1 +/- 0.9 days. The disposition of JM-40 was similar to that of ultrafilterable Pt in respect to t1/2 alpha (10 and 13 min), t1/2 beta (44 and 57 min), volumes of distribution Vc (11 and 121) and Vss (17 and 201), systemic clearance (256 and 223 ml min-1), renal clearance (69 and 73 ml min-1) and metabolic clearance (183 and 154 ml min-1). During the first 6 h 27 +/- 9% of the administered dose was excreted as JM-40. Cumulative platinum excretion in the urine amounted to 29 +/- 13% and 60 +/- 13% over the first 6 h, 24 h and 5 days, respectively. The uptake of platinum in red blood cells was limited, comprising only 0.24 +/- 0.12% of the administered dose. Although JM-40 and carboplatin are structurally closely related, pharmocokinetics and toxicity of JM-40 were more similar to cis-platin than to carboplatin. 相似文献
2.
3.
J B Jensen J J Pease R ten Bensel B D Garfinkel 《Journal of the American Academy of Child and Adolescent Psychiatry》1991,30(5):784-790
The ratio of growth hormone response to clonidine and L-dopa challenge was compared in 74 boys: 15 with purported physical abuse, 7 with purported sexual abuse, 13 normal controls, and 39 psychiatric controls. Sexually abused boys demonstrate a statistically significant elevated ratio of growth hormone response to clonidine versus response to L-dopa. Physically abused boys demonstrate lower clonidine/L-dopa growth hormone response ratios compared with controls. These effects widen with increasing physical development. 相似文献
4.
S J Graafsma H Wollersheim H T Droste M A ten Dam L J van Tits J Reyenga J F Rodrigues de Miranda T Thien 《Clinical science (London, England : 1979)》1991,80(4):325-331
1. alpha 2-Adrenoceptors on platelet membranes and beta 2-adrenoceptors on lymphocytes were studied in 24 patients with primary Raynaud's phenomenon and in 24 age- and sex-matched control subjects. In two subgroups, a standardized mental arithmetic test and a finger-cooling test were performed. 2. Baseline blood pressure, heart rate and forearm blood flow did not differ between the two groups. 3. Baseline skin microcirculation (laser Doppler flux) was decreased in primary Raynaud's phenomenon (19 +/- 15 arbitrary units) compared with control subjects (33 +/- 14 arbitrary units) (P less than 0.01). 4. Baseline plasma noradrenaline concentration (2.00 +/- 1.44 versus 1.16 +/- 0.36 nmol/l) and alpha 2-adrenoceptor density (301 +/- 119 versus 210 +/- 82 fmol/mg) were increased in patients with primary Raynaud's phenomenon in comparison with the control subjects. The alpha 2-adrenoceptor density/beta 2-adrenoceptor density ratio in patients with primary Raynaud's phenomenon was, with a value of 0.37 +/- 0.04, higher than in the control subjects, where a value of 0.25 +/- 0.02 was measured (P less than 0.001). Plasma adrenaline concentration, beta 2-adrenoceptor density and the antagonist affinity to both receptor subtypes did not differ between both groups under baseline conditions. 5. Whereas during the finger-cooling test no differences were seen in the responses of the parameters measured, the mental arithmetic test induced an increase in laser Doppler flux in patients with primary Raynaud's phenomenon and a decrease in the control group.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
5.
Hillary R Bogner Mark S Cary Martha L Bruce Charles F Reynolds Benoit Mulsant Thomas Ten Have George S Alexopoulos 《The American journal of geriatric psychiatry》2005,13(10):861-868
OBJECTIVE: The authors described the influence of specific medical conditions on clinical remission and response of major depression (MDD) in a clinical trial evaluating a care-management intervention among older primary-care patients. METHODS: Adults age 60 years and older were randomly selected and screened for depression. Participants were randomly assigned to Usual Care or to an Intervention with a depression care-manager offering algorithm-based care for MDD. In all, 324 adults meeting criteria for MDD were included in these analyses. Remission and response was defined by a score on the Hamilton Rating Scale for Depression <10 and by a decrease from baseline of > or =50%, respectively. Medical comorbidity was ascertained through self-report. Cognitive impairment was defined by a score <24 on the Mini-Mental State Exam (MMSE). RESULTS: In Usual Care, rates of remission were faster in persons who reported atrial fibrillation (AF) than in persons who did not report AF and slower in persons who reported chronic pulmonary disease than in persons who did not report chronic pulmonary disease; rates of response were less stable in persons with MMSE <24 than in those with MMSE > or =24. In the Intervention condition, none of the specific chronic medical conditions were significantly associated with outcomes for MDD. CONCLUSIONS: Because disease-specific findings were observed in persons who received Usual Care but not in persons who received more intensive treatment in the Intervention condition, our results suggest that the association of medical comorbidity and treatment outcomes for MDD may be determined by the intensity of treatment for depression. 相似文献
6.
7.
8.
9.
J M G?tz A J Nielander P J Brouwers C H ten Napel 《Nederlands tijdschrift voor geneeskunde》1992,136(33):1611-1613
Transfusion-associated symptomatic HIV infection in four patients led to death in two patients and to development of serious neurological sequelae in a third patient who also transmitted HIV infection to his spouse. The tardy diagnosis of HIV-associated disease in all cases can be ascribed to ignoring the earlier blood transfusion as a possible cause of HIV infection. This was due partly to advanced age of the patients and partly to lack of familiarity of the attending physicians with HIV-associated problems. This resulted in a substantial doctor's delay. 相似文献
10.
Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol. 总被引:1,自引:0,他引:1
Results are presented of a Phase III international multicentre trial to study the effect of a new low-dose oral contraceptive (OC) containing 20 micrograms ethinylestradiol and 150 micrograms desogestrel (Mercilon) regarding efficacy, cycle control, blood pressure, and acceptability. Altogether 1,684 women from 12 European countries were included in the study. Four pregnancies occurred, 3 of them patient failures, one tablet failure. The overall Pearl Index was 0.20. The frequency of irregular bleeding was comparable to that recorded with other commonly used low-dose OCs. No serious side effects occurred. The incidence of the most frequently reported subjective side effects--headache, nausea and breast tension--was already low after the first cycle of treatment and decreased to below pretreatment levels with continued use. There was a small increase in mean body weight, which was confined essentially to young women. The preparation did not affect the mean systolic or diastolic blood pressure. This new preparation has thus proved to be an effective, safe and well-accepted ultra low-dose oral contraceptive. 相似文献